Drugs / RP-A701
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07137338 | Jun 2026 → Jun 2029 expected | dilated cardiomyopathy | Rocket Pharmaceuticals Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RP-A701 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07137338 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid” NCT07137338 ↗ |
| Route | Intravenous | “single intravenous dose” NCT07137338 ↗ |